FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

NCT03841110 | Completed Phase 1 FDA Drug

• 1 other identifier: FT500-101
• Study Type: interventional
• Target: 37
• Locations: 1 country
• Sites: 4

Brief Summary

FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the clinical investigation of FT500 as monotherapy and in combination with ICI in participants with advanced solid tumors.

Conditions

Advanced Solid Tumors; Lymphoma; Gastric Cancer; Colorectal Cancer; Head and Neck Cancer; Squamous Cell Carcinoma; EGFR Positive Solid Tumor; HER2-positive Breast Cancer; Hepatocellular Carcinoma; Small Cell Lung Cancer; Renal Cell Carcinoma; Pancreas Cancer; Melanoma; NSCLC; Urothelial Carcinoma; Cervical Cancer; Microsatellite Instability; Merkel Cell Carcinoma

Keywords

Advanced Solid Tumor; Lymphoma; Breast Cancer; Head and Neck Cancer; Head and Neck; Squamous Cell Carcinoma; Gastric Cancer; Colorectal Cancer; Immunotherapy; NK cell therapy; Melanoma; Checkpoint Inhibitor; Immune Checkpoint Inhibitor; Monoclonal Antibody; Cell therapy; Cellular therapy; nivolumab; pembrolizumab; atezolizumab

Outcome Measures

Primary Outcomes (1)

• The incidence of participants with Dose Limiting Toxicities (DLTs) within each dose level cohort.

  The incidence of participants with DLTs within each assessed dose level cohort to determine the maximum tolerated dose (MTD) or maximum assessed dose (MAD).

  Day 29

Secondary Outcomes (2)

• Objective-response rate (ORR)

  Day 29 and every 8 weeks thereafter through Day 366

• Duration of FT500 persistence

  Day 1 through Day 366

Study Arms (3)

FT500 Monotherapy

EXPERIMENTAL

FT500 administered once weekly for 3 weeks as a monotherapy

Drug: FT500; Drug: Cyclophosphamide; Drug: Fludarabine

FT500 in Combination with Immune Checkpoint Inhibitor

EXPERIMENTAL

FT500 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab.

Drug: FT500; Drug: Nivolumab; Drug: Pembrolizumab; Drug: Atezolizumab; Drug: Cyclophosphamide; Drug: Fludarabine

FT500 +IL-2 in Combination with Immune Checkpoint Inhibitor

EXPERIMENTAL

FT500 + IL-2 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab.

Drug: FT500; Drug: Nivolumab; Drug: Pembrolizumab; Drug: Atezolizumab; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: IL-2

Interventions

FT500 DRUG

FT500 is an allogeneic, iPSC-derived Natural Killer (NK) cell cancer immunotherapy

FT500 +IL-2 in Combination with Immune Checkpoint Inhibitor; FT500 Monotherapy; FT500 in Combination with Immune Checkpoint Inhibitor

Nivolumab DRUG

Immune Checkpoint Inhibitor

Also known as: OPDIVO

FT500 +IL-2 in Combination with Immune Checkpoint Inhibitor; FT500 in Combination with Immune Checkpoint Inhibitor

Pembrolizumab DRUG

Immune Checkpoint Inhibitor

Also known as: KEYTRUDA

FT500 +IL-2 in Combination with Immune Checkpoint Inhibitor; FT500 in Combination with Immune Checkpoint Inhibitor

Atezolizumab DRUG

Immune Checkpoint Inhibitor

Also known as: TECENTRIQ

FT500 +IL-2 in Combination with Immune Checkpoint Inhibitor; FT500 in Combination with Immune Checkpoint Inhibitor

Cyclophosphamide DRUG

Lympho-conditioning agent

FT500 +IL-2 in Combination with Immune Checkpoint Inhibitor; FT500 Monotherapy; FT500 in Combination with Immune Checkpoint Inhibitor

Fludarabine DRUG

Lympho-conditioning agent

FT500 +IL-2 in Combination with Immune Checkpoint Inhibitor; FT500 Monotherapy; FT500 in Combination with Immune Checkpoint Inhibitor

IL-2 DRUG

Biologic response modifier

Also known as: Proleukin, Aldesleukin

FT500 +IL-2 in Combination with Immune Checkpoint Inhibitor

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. Diagnosis of the following, as per Regimen Cohort:
• A. Regimen A: FT500 Monotherapy (Dose Escalation): An advanced solid tumor malignancy, including lymphoma, in a participant who has failed or refused available FDA-approved therapies and is now a candidate for salvage therapy.
• B. Regimen B and BB (Dose Escalation): FT500 (+ IL-2, Regimen BB only) + ICI: An advanced solid tumor malignancy, including lymphomas, that has progressed on treatment with at least one ICI (ie, nivolumab, pembrolizumab or atezolizumab), in a participant who has also failed or refused other available approved therapies and is now a candidate for salvage therapy.
• C. Regimen B(Dose Expansion): FT500 (+ IL-2, Regimen BB only) + ICI An advanced solid tumor malignancy or lymphoma in a participant with disease relapse or progression on an ICI (nivolumab, pembrolizumab, or atezolizumab) in an approved indication per the respective USPI.
• \. Willingness to provide informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
• \. Age \>18 years old at the time of signing the ICF. 4. Presence of measurable disease by iRECIST or RECIL criteria, assessed before the start of lympho-conditioning and within 28 days prior to Day 1.
• \. Contraceptive use by women or men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
• a. Female participants: Women of childbearing potential (WOCBP) must use a highly effective form of contraception from the screening visit until at least 12 months after the final dose of CY, at least 4 months after the final dose of FT500, at least 4 months after the final dose of pembrolizumab, and at least 5 months after the final dose of nivolumab or atezolizumab, whichever is latest.
• b. Male participants: Males must be sterile (biologically or surgically) or use a highly effective method of contraception from the screening visit until at least 14 months after the final dose of CY, at least 6 months after the final dose of FT500, at least 6 months after the final dose of pembrolizumab, and at least 7 months after the final dose of nivolumab or atezolizumab, whichever is latest.
• \. Willingness to comply with study procedures through the planned study duration. For patients with \>1 measurable lesion, agreement to undergo a biopsy from a safely accessible site per Investigator assessment for exploratory biomarker assessments.
• \. Provision of signed and dated ICF to agree to participate, at time of withdrawal or completion of this study, in Fate Therapeutics' long-term, non-interventional, observational study, FT-003.

You may not qualify if:

• All participants:
• \. Females who are pregnant or breastfeeding. 2. ECOG performance status ≥ 2. 3. Evidence of insufficient organ function as determined by any one of the following: 3a. Neutrophils \<1000/µL or platelets \<75,000/µL. 3b. Estimated creatinine clearance \<50 mL/minute (Cockcroft-gault). 3c. Total bilirubin \>2 x upper limit normal (ULN) with the exception of participants with Gilbert's Syndrome or known liver metastases.
• d. Aspartate aminotransferase (AST) \>3 x ULN, or alanine aminotransferase (ALT) \>3 x ULN. For participants with known liver metastases, AST or ALT \>5 x ULN.
• e. Oxygen saturation \<90% on room air. 3f. Left ventricular ejection fraction (LVEF) \<40% (eg by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan).
• Receipt of any biological therapy, chemotherapy, or radiation (except palliative radiation) within 2 weeks prior to Day 1. Participants in Regimen B currently taking an ICI must interrupt ICI dosing at least 2 weeks prior to Day 1.
• \. CNS metastases that have not been treated; or treated CNS metastases that have not been stable for at least 4 weeks.
• \. Clinically significant cardiovascular disease, including stroke or myocardial infarction within 6 months prior to first study medication; or the presence of unstable angina or congestive heart failure of New York Heart Association grade 2 or higher.
• \. Currently receiving or likely to require systemic immunosuppressive therapy (eg, prednisone \>5 mg daily) for any reason from Day -7 to Day 29.
• \. Uncontrolled infections. 9. Known allergy to the following FT500 components: Albumin (Human) or DMSO. 10. Presence of any medical or social issues that are likely to interfere with study conduct, or may cause increased risk to participant.
• \. Any medical condition or clinical laboratory abnormality that, per Investigator or Medical Monitor judgement, precludes safe participation in and completion of the study, or that could affect compliance with protocol conduct or interpretation of results. Participants who have had prior receipt of a Fate Therapeutics investigational human iPSC product may be eligible for the study with approval from the Medical Monitor.
• \. Participants who experienced an ICI-related adverse reaction that resulted in discontinuation of the ICI.
• \. Presence or history of autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's disease, autoimmune disease associated with lymphoma, Crohn's disease, ulcerative colitis), except for participants with isolated vitiligo, atopic dermatitis, controlled hypoadrenalism or hypopituitarism, and controlled thyroid disease.
• \. Participants who have received an allograft organ transplant.

Sponsors & Collaborators

• Fate Therapeutics: lead

Study Sites (4)

UCSD Moores Cancer Center

San Diego, California, 92093, United States

Location

University of Minnesota Masonic Cancer Center

Minneapolis, Minnesota, 55455, United States

Location

Hackensack University Medical Center/John Theurer Cancer Center

Hackensack, New Jersey, 07601, United States

Location

MD Anderson Cancer Center

Houston, Texas, 77030, United States

Location

MeSH Terms

Conditions

Lymphoma; Stomach Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular; Small Cell Lung Carcinoma; Carcinoma, Renal Cell; Pancreatic Neoplasms; Melanoma; Carcinoma, Transitional Cell; Uterine Cervical Neoplasms; Microsatellite Instability; Carcinoma, Merkel Cell; Breast Neoplasms

Interventions

Nivolumab; pembrolizumab; atezolizumab; Cyclophosphamide; fludarabine; Interleukin-2; aldesleukin

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases; Intestinal Neoplasms; Colonic Diseases; Intestinal Diseases; Rectal Diseases; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms, Squamous Cell; Adenocarcinoma; Liver Neoplasms; Liver Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Lung Diseases; Respiratory Tract Diseases; Kidney Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Kidney Diseases; Urologic Diseases; Male Urogenital Diseases; Endocrine Gland Neoplasms; Pancreatic Diseases; Endocrine System Diseases; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Nevi and Melanomas; Skin Neoplasms; Skin Diseases; Skin and Connective Tissue Diseases; Uterine Neoplasms; Genital Neoplasms, Female; Uterine Cervical Diseases; Uterine Diseases; Genital Diseases, Female; Genital Diseases; Genomic Instability; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Polyomavirus Infections; DNA Virus Infections; Virus Diseases; Infections; Tumor Virus Infections; Carcinoma, Neuroendocrine; Breast Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins; Phosphoramide Mustards; Nitrogen Mustard Compounds; Mustard Compounds; Hydrocarbons, Halogenated; Hydrocarbons; Organic Chemicals; Phosphoramides; Organophosphorus Compounds; Interleukins; Cytokines; Intercellular Signaling Peptides and Proteins; Peptides; Lymphokines; Biological Factors

Study Officials

• Fate Trial Disclosure

  FateTrialDisclosure@fatetherapeutics.com

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 12, 2019
• First Posted: February 15, 2019
• Study Start: February 15, 2019
• Primary Completion: November 15, 2022
• Study Completion: November 15, 2022
• Last Updated: May 1, 2023

Record last verified: 2023-04

Locations

US (4)